Antibody–drug conjugates have emerged as a powerful tool ... Traditional ADCs are engineered with a DNA-damaging or microtubule-targeting agent tethered to a monoclonal antibody.

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Chimera Biotec, founded in 2000 as a spin-off from academic research in Germany, has implemented its proprietary DNA-antibody conjugates within the highly innovative Imperacer product line ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

SMi is proud to present their 6th annual Antibodies and Antibody Drug Conjugates conference, being held at the Copthorne Tara Hotel, London, UK on the 9 th – 10 th April 2018. With an every ...

On-demand video webcast now available hereBOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal antibodies are derived from hybridoma technology, the recombinant antibodies are ...

Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” ...

With a strong track record of innovation and quality, GBI supports the development of complex biologics, including monoclonal antibodies, conjugates, and other therapeutic modalities. For more ...